Treace Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference
Treace Medical Concepts, Inc. (TMCI), a medical technology company specializing in bunion and midfoot deformity treatments, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's CEO, John T. Treace, and CFO, Mark L. Hair, will engage in a fireside chat on September 5, 2024, at 10:00 am ET.
Investors can access a live webcast and replay of the event through Treace's investor relations website. The company encourages stakeholders to regularly check their website for important updates and information.
Treace Medical Concepts, Inc. (TMCI), un'azienda tecnologica medica specializzata nei trattamenti per alluce valgo e deformità del mezzo piede, ha annunciato la sua partecipazione alla 22ª Conferenza Annuale Globale sulla Salute di Morgan Stanley. Il CEO dell'azienda, John T. Treace, e il CFO, Mark L. Hair, parteciperanno a un'intervista informale il 5 settembre 2024, alle 10:00 ET.
Gli investitori possono accedere a una trasmissione in diretta e a una registrazione dell'evento tramite il sito web delle relazioni con gli investitori di Treace. L'azienda invita gli stakeholder a controllare regolarmente il proprio sito per aggiornamenti e informazioni importanti.
Treace Medical Concepts, Inc. (TMCI), una empresa de tecnología médica especializada en tratamientos para juanetes y deformidades del mediopié, ha anunciado su participación en la 22ª Conferencia Anual Global de Salud de Morgan Stanley. El CEO de la compañía, John T. Treace, y el CFO, Mark L. Hair, participarán en una charla informal el 5 de septiembre de 2024, a las 10:00 a.m. ET.
Los inversores pueden acceder a una transmisión en vivo y a una repetición del evento a través del sitio web de relaciones con inversores de Treace. La empresa anima a las partes interesadas a visitar regularmente su sitio para obtener actualizaciones e información importante.
Treace Medical Concepts, Inc. (TMCI), 발가락 및 중족골 변형 치료를 전문으로 하는 의료 기술 회사가 모건 스탠리 제22회 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 CEO인 John T. Treace와 CFO인 Mark L. Hair는 2024년 9월 5일 오전 10시(동부 표준시)에 화상 대화에 참여합니다.
투자자들은 Treace의 투자자 관계 웹사이트를 통해 이벤트의 라이브 웹캐스트 및 재생에 접속할 수 있습니다. 회사는 이해 관계자들에게 중요한 업데이트 및 정보를 위해 정기적으로 웹사이트를 확인할 것을 권장합니다.
Treace Medical Concepts, Inc. (TMCI), une entreprise de technologie médicale spécialisée dans les traitements des oignons et des déformations du médio-pied, a annoncé sa participation à la 22e Conférence Annuelle Mondiale sur la Santé de Morgan Stanley. Le PDG de l’entreprise, John T. Treace, et le CFO, Mark L. Hair, participeront à une discussion amicale le 5 septembre 2024 à 10h00 ET.
Les investisseurs peuvent accéder à un webinaire en direct et à un replay de l'événement via le site des relations investisseurs de Treace. L'entreprise encourage les parties prenantes à vérifier régulièrement son site pour des mises à jour et des informations importantes.
Treace Medical Concepts, Inc. (TMCI), ein Medizintechnikunternehmen, das sich auf die Behandlung von Hallux Valgus und Mittelfußdeformitäten spezialisiert hat, hat seine Teilnahme an der 22. jährlichen globalen Gesundheitskonferenz von Morgan Stanley angekündigt. Der CEO des Unternehmens, John T. Treace, und der CFO, Mark L. Hair, werden am 5. September 2024 um 10:00 Uhr ET an einem informellen Gespräch teilnehmen.
Investoren können über die Investor-Relations-Website von Treace auf einen Live-Webcast und eine Aufzeichnung der Veranstaltung zugreifen. Das Unternehmen ermutigt die Interessengruppen, regelmäßig ihre Website auf wichtige Aktualisierungen und Informationen zu überprüfen.
- None.
- None.
PONTE VEDRA, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, 2024, beginning at approximately 10:00 am ET.
A live webcast and replay of the fireside chat will be available on the Company’s investors relations website at https://investors.treace.com/.
Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion patients, Treace has introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities. The Company continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate™ Rapid Compression Implants, an innovative fixation platform with broad versatility. For more information, please visit www.treace.com.
To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940
Investors:
Gilmartin Group
Vivian Cervantes
IR@treace.net
FAQ
When is Treace Medical Concepts (TMCI) participating in the Morgan Stanley Healthcare Conference?
Who will represent Treace Medical Concepts (TMCI) at the Morgan Stanley Healthcare Conference?
How can investors access Treace Medical Concepts' (TMCI) fireside chat at the Morgan Stanley conference?
What are the main products of Treace Medical Concepts (TMCI)?
